Stock Market Reviews

Read and share opinions on BMY (Bristol-Myers Squibb Company) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus
  Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple recent product launches and the announcement of a new R&D facility. The company has agreed to acquire Orbital Therapeutics, expanding its presence in RNA based medicines. New collaborations with BioNTech and Philochem target next generation cancer and immunology treatments. Management has paired these moves with plans for major cost savings and added manufacturing capacity. Bristol-Myers Squibb,...
  Feb 13, 2026
• Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY)
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds. Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted […]
  Feb 13, 2026
• Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the best long-term stocks to invest in for retirement. On February 10, Bernstein SocGen Group reiterated its Market Perform rating and $58 price target on Bristol-Myers Squibb Company (NYSE:BMY) following strong fourth-quarter results, with revenue of $12.5 billion and EPS of $1.26 both beating consensus. The firm highlighted […]
  Feb 12, 2026
• The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call
  Bristol-Myers Squibb’s fourth quarter saw continued momentum in its growth portfolio, which management credited as the primary driver behind the company’s positive results. CEO Christopher Boerner highlighted significant contributions from newer products such as Opdualag, Breyanzi, and Camzyos, each surpassing $1 billion in annual sales, and emphasized their early-stage potential. The company also benefited from steady uptake in recently launched therapies, with Reblozyl notably achieving over $
  Feb 12, 2026
• This Is Graco’s Dividend Score After Paying Investors
  Graco just paid investors $0.295 per share on February 4, 2026, marking the company’s 27th consecutive year of quarterly dividend payments. This industrial equipment manufacturer has quietly built one of the more consistent dividend growth records in the specialty machinery sector, with a 5-year compound annual growth rate of approximately 9.4%. But consistency alone doesn’t ... This Is Graco’s Dividend Score After Paying Investors
  Feb 12, 2026
• Robert A. Winn Excellence in Clinical Trials Award Program Announces Third Cohort of Physician-Researchers for the Clinical Investigator Leadership Award
  Bristol Myers Squibb Foundation is proud to support Conquer Cancer's EveryGrant and the American Heart Association to Advance Clinical Trials Leadership in Oncology and Cardiovascular Research Originally published by The Robert A. Winn Excellence ...
  Feb 11, 2026
• EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
  DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
  Feb 11, 2026
• Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
  Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
  Feb 11, 2026
• Is Bristol Myers Squibb (BMY) Pricing Reflecting Its Recent Share Price Rebound?
  If you are wondering whether Bristol-Myers Squibb is attractively priced right now, this article will walk through what the current share price could mean for long term investors. The stock last closed at US$60.77, with returns of 8.7% over 7 days, 8.8% over 30 days, 13.7% year to date, 15.0% over 1 year, negative 4.8% over 3 years, and 23.5% over 5 years. These figures give important context for any value discussion. Recent coverage has focused on Bristol-Myers Squibb's position in large...
  Feb 10, 2026
• Bristol-Myers Squibb (BMY) Is Up 8.7% After Profit Rebound And Pipeline Outlook - Has The Bull Case Changed?
  Bristol-Myers Squibb recently reported its fourth-quarter and 2025 results, showing broadly stable annual revenue of about US$48.19 billion and a swing from a prior-year net loss to net income of US$7.05 billion, alongside improved earnings per share from continuing operations. Management’s upbeat guidance, stronger performance from its growth portfolio, and plans for multiple pivotal late-stage trial readouts in 2026 have renewed attention on the company’s product pipeline and its efforts...
  Feb 10, 2026
• Bristol Myers Squibb AI Trials And 2026 Readouts Reframe Valuation
  Bristol Myers Squibb (NYSE:BMY) has entered a partnership with Evinova to use AI tools in clinical trial design and execution. The company is focusing this collaboration on speeding up and refining development across its drug pipeline. Analysts have recently updated success probabilities for several key pipeline therapies, reflecting closer attention to upcoming programs. Management has highlighted 2026 as a year with multiple pivotal clinical data readouts expected across major...
  Feb 10, 2026
• Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?
  BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.
  Feb 10, 2026
• Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating
  Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Most Profitable Undervalued Stocks to Buy On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating. The firm significantly increased its estimated probability of success for iber/mezi to 90% from 33% and lifted its […]
  Feb 9, 2026
• Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
  BAAR, Switzerland, February 09, 2026--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
  Feb 9, 2026
• BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
  BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
  Feb 9, 2026
• Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism
  Earnings-triggered move in Bristol-Myers Squibb stock Bristol-Myers Squibb (BMY) is back in focus after its latest earnings release, which showed higher profitability, flat full year revenue, and guidance that came in above analyst expectations. See our latest analysis for Bristol-Myers Squibb. The recent earnings release, analyst upgrades around key pipeline drugs, and news of AI-enabled clinical trial work have all fed into a sharp rebound. A 24.73% 90 day share price return and a 5 year...
  Feb 9, 2026
• Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug
  We recently published 12 Stocks Jim Cramer Talked About. Bristol Myers Squibb Company (NYSE:BMY) is one of the stocks that Jim Cramer talked about. Bristol Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. Its shares are up by 7.5% over the past year and by 15.4% year-to-date. Piper Sandler […]
  Feb 7, 2026
• Bristol Myers price target raised to $40 from $37 at Morgan Stanley
  Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $40 from $37 and keeps an Underweight rating on the shares. 2026 revenue and EPS guidance came in above consensus, but was driven by a higher than expected Eliquis guide, the analyst tells investors in a research note.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximi
  Feb 7, 2026
• BMS reports flat revenue growth for full-year 2025
  The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.
  Feb 6, 2026
• Bristol Myers Squibb Q4 Earnings Call Highlights
  Bristol Myers Squibb (NYSE:BMY) executives emphasized “focused execution” in 2025 and pointed to continued momentum entering 2026, as the company’s growth portfolio increasingly offsets declines in legacy products. On the company’s fourth-quarter earnings call, management highlighted strong contribu
  Feb 6, 2026

• CashCraze

  Feb 14, 2026

  $BMY This established player continues to innovate within the pharmaceutical landscape, with promising developments in its pipeline. The strong commitment to research and development bodes well for its future market positioning.

  Buy

• VolatilityViper

  Feb 13, 2026

  $BMY Big pharma making promises it can't keep. Shocking.

  Sell

• TickerPhantom

  Feb 13, 2026

  $BMY As a leader in biopharmaceuticals, this organization continues to push the boundaries of medical research and innovation. Its strong pipeline of new therapies indicates a commitment to improving patient outcomes and expanding market influence.

  Buy

• TheMemeInvestor

  Feb 12, 2026

  $BMY Got that pharma game on lock, makin’ moves like a boss!

  Buy

• DiamondHandz

  Feb 11, 2026

  $BMY This one’s got that healing vibe, folks! It’s all about the comeback.

  Buy

• ShortSqueezeX

  Feb 9, 2026

  $BMY This stock is like a wise old owl: it knows a lot and seems to always have the best moves up its sleeve!

  Buy

• BullBrawler

  Feb 9, 2026

  $BMY Big Pharma peddling hope, but mostly hype.

  Sell

• BagholderElite

  Feb 9, 2026

  $BMY This one's got that steady hustle, always delivering the goods!

  Buy

• BullishVanguard

  Feb 8, 2026

  $BMY Another pharmaceutical giant? Just what we need in a crowded market.

  Sell

• TheEquityEdge

  Feb 7, 2026

  $BMY This pharmaceutical giant is advancing its pipeline with promising treatments, reflecting a strong commitment to innovation in healthcare.

  Buy

• ShortSqueezeX

  Feb 7, 2026

  $BMY They've got more research going on than your average high school science fair. Expect some serious brainpower here!

  Buy

• DividendDemon

  Feb 6, 2026

  $BMY This pharma giant is like a doctor at a party—always bringing the good drugs and making everyone feel better!

  Buy

• RiskReaper

  Feb 6, 2026

  $BMY As a key player in the biopharmaceutical sector, this company continues to innovate with groundbreaking therapies that address critical health issues. Its robust pipeline and ongoing research efforts signal potential for sustained impact in the healthcare market.

  Buy

• RiskRanger

  Feb 6, 2026

  $BMY This company is like the superhero of the pharma world, swooping in to save us from the villains of disease! Just don’t ask about its cape size.

  Buy

• TendieTitan

  Feb 6, 2026

  $BMY This healthcare giant is like the superhero of pills! Wear your cape when investing here.

  Buy

• OptionOverlord

  Feb 6, 2026

  $BMY This pharmaceutical giant could turn your frown upside down faster than you can say 'pills and thrills!'

  Buy

• TradeRebel

  Feb 6, 2026

  $BMY With a pipeline that could change the game, the excitement is electric—but will regulatory hurdles dim the light? Investors are on edge; the stakes have never felt higher!

  Buy

• BearishBoi

  Feb 6, 2026

  $BMY This stock is like comfort food; always makes you feel better, even when times are tough. Plus, no calories involved!

  Buy

• BullishBard

  Feb 5, 2026

  $BMY This company's got more ups and downs than a rollercoaster—hold on tight and enjoy the ride, or just scream!

  Buy

• DiamondHandz

  Feb 4, 2026

  $BMY This company’s got that pharma hustle – big moves on the horizon!

  Buy

• BearMarketSurvivor

  Feb 4, 2026

  $BMY Big pharma flex, they ain't playin' around with those new treatments!

  Buy

• RiskAssassin

  Feb 3, 2026

  $BMY With looming patent expirations and intense competition from generics, the pressure is on this pharmaceutical giant. The stakes are sky-high, and every quarter feels like a ticking time bomb for investors.

  Sell

• ChartPhantom

  Feb 3, 2026

  $BMY This stock’s got more ups and downs than a rollercoaster – and I don’t even need to scream for help!

  Buy

• BullRaid

  Feb 2, 2026

  $BMY A giant that’s lost its way, good luck.

  Sell

• PnLReaper

  Feb 1, 2026

  $BMY A powerhouse in the pharmaceutical industry, this company continues to drive innovation with a strong pipeline of drugs. Their strategic focus on research and development is likely to sustain long-term growth.

  Buy

• BullishCraze

  Feb 1, 2026

  $BMY This leading biopharmaceutical company continues to advance in its research and development endeavors. Their pipeline of innovative therapies is promising and may enhance their market position significantly.

  Buy

• CodeTrader

  Feb 1, 2026

  $BMY The ongoing developments and surprises in the pharmaceutical world keep everybody on edge; one moment it's soaring, the next, it's a steep dive. Can you handle the tension?

  Buy

• BullRaid

  Feb 1, 2026

  $BMY This one’s riding the coattails of hope at best.

  Sell

• FiscalFury

  Feb 1, 2026

  $BMY If life were a pharmacy, this company would be the cool aisle with all the fun stuff. Who doesn’t love a good cure?

  Buy

• CapitalVortex

  Jan 31, 2026

  $BMY With a pipeline of potential breakthroughs that could either make or break their future, the stakes have never been higher for this pharmaceutical giant. The pressure to succeed is palpable, and time is running out!

  Buy

• YOLOTrader

  Jan 31, 2026

  $BMY This giant is like your grandma baking cookies—always got the right recipe to sweeten up the healthcare game!

  Buy

• FiscalRiot

  Jan 30, 2026

  $BMY With breakthroughs in pharmaceuticals constantly in flux, can this giant maintain its edge or risk getting overshadowed by new contenders? The stakes for innovation and investment are sky-high right now!

  Buy

• MarketReaper

  Jan 30, 2026

  $BMY If this company were a character, they’d be the reliable best friend who always has your back and good advice!

  Buy

• CashOverload

  Jan 30, 2026

  $BMY Ideal momentum environment for bulls.

  Buy

• CodeAndCapital

  Jan 30, 2026

  $BMY Bearish multi-timeframe confluence.

  Sell

• OptionSpectre

  Jan 30, 2026

  $BMY An overhyped giant that thinks it’s still at the top of its game.

  Sell

• RiskProtocol

  Jan 29, 2026

  $BMY With healthcare stakes at an all-time high, this company is under immense pressure to deliver. Will their innovations shine, or will they be left scrambling for relevance?

  Sell

• MarketRender

  Jan 29, 2026

  $BMY In the ever-evolving pharmaceutical landscape, this giant must navigate patent cliffs and emerging competitors. The stakes have never been higher—can they adapt quickly enough?

  Buy

• ProfitGremlin

  Jan 29, 2026

  $BMY Dropping lifesavers in the pharma game, this team’s got that healing touch.

  Buy

• StonkDestroyer

  Jan 28, 2026

  $BMY Big pharma wrestling with its own shadows; good luck with that.

  Sell

• CapitalCarnage

  Jan 28, 2026

  $BMY This one’s only thriving thanks to luck, not skill.

  Sell

• TheAlphaDagger

  Jan 28, 2026

  $BMY This healthcare giant is battling both innovation and looming patent expirations. Can it maintain its edge in a rapidly shifting environment, or will it succumb to the pressure?

  Buy

• DividendDemon

  Jan 27, 2026

  $BMY It's like that friend who always has the best recommendations for movies—seems to know what the people want every time!

  Buy

• TraderFury

  Jan 27, 2026

  $BMY With the pharmaceutical industry evolving, every decision feels like a game of high stakes poker. Are they holding the winning hand, or is it time for a serious reassessment?

  Buy

• StonkSamurai

  Jan 26, 2026

  $BMY This joint’s packin’ heat in the pharma game, for sure!

  Buy

• MarketMatrix

  Jan 24, 2026

  $BMY This stock is like the superhero of the group—always swooping in to save the day when things get tough!

  Buy

• CryptoCobra

  Jan 23, 2026

  $BMY This stock’s like the ultimate MVP—always there when you need it, but don’t forget to share the glory!

  Buy

• DividendDemon

  Jan 22, 2026

  $BMY When it comes to health and keeping things in check, this company is like your mom reminding you to eat your veggies!

  Buy

• BullRaid

  Jan 22, 2026

  $BMY This company is just a slow-moving behemoth in a race of sprinters.

  Sell

• TheAlphaDagger

  Jan 21, 2026

  $BMY An industry giant, yet the pressure is relentless. Can they keep pace with rapid changes, or is their reign coming to an end? The tension is real!

  Sell

• AlphaVandal

  Jan 21, 2026

  $BMY The only thing thriving here is the competition.

  Sell

• StockShotz

  Jan 20, 2026

  $BMY This company’s drugs are like magic potions; they could make even a wizard jealous!

  Buy

• OptionNomad

  Jan 18, 2026

  $BMY Big pharma's playing a dangerous game, and the stakes are higher than ever. With competition looming and regulations tightening, can they maintain their edge? The pressure is escalating!

  Sell

• WallStreetWolf

  Jan 17, 2026

  $BMY This company is like your favorite superhero—fighting off diseases and saving the day, one patient at a time. Who doesn’t love a good story with a happy ending?

  Buy

• TradingNomad

  Jan 17, 2026

  $BMY The competition is fierce, and the landscape keeps shifting! Despite recent trials, there's a glimmer of hope that could turn things around. Is it enough to sway the tide?

  Buy

• ShortSurge

  Jan 16, 2026

  $BMY A powerhouse in the pharmaceutical landscape, this company continues to diversify its portfolio, focusing on innovation that addresses critical healthcare challenges, which bodes well for its future prospects.

  Buy

• TheRiskDealer

  Jan 16, 2026

  $BMY In the ever-evolving pharmaceutical landscape, this giant is racing against time with its blockbuster drugs! The stakes are sky-high—will it conquer or falter?

  Buy

• TrendStalker

  Jan 16, 2026

  $BMY Risk/reward skewed heavily upward.

  Buy

• ShortCircuit

  Jan 16, 2026

  $BMY This one’s stumbling like a drunk on a tightrope.

  Sell

• StonkViking

  Jan 16, 2026

  $BMY Dip-buying activity showing strong conviction.

  Buy

• BearHunter

  Jan 15, 2026

  $BMY When it comes to pharma, this one has the patients begging for more! 💊🤪

  Buy

• LiquidLegend

  Jan 15, 2026

  $BMY Breakout above resistance looks imminent.

  Buy

• RiskRanger

  Jan 15, 2026

  $BMY This company is like that reliable friend who always brings snacks to the party—got your back when it counts!

  Buy

• DiamondHands

  Jan 15, 2026

  $BMY They’ve got the magic potion for health – just hope there’s no side effects called 'market volatility'!

  Buy

• TickerFlux

  Jan 15, 2026

  $BMY The pressure is mounting as competitors close in. Strong fundamentals are crucial, but will they hold up under scrutiny? It’s a nail-biter!

  Sell

• WallStreetWolf

  Jan 14, 2026

  $BMY Imagine this company as the coolest science teacher—full of knowledge, but sometimes you're just not ready for that AP exam.

  Buy

• GainMachine

  Jan 13, 2026

  $BMY This company knows how to cook up some good meds! They’re basically the chefs of healthcare, dishing out wellness!

  Buy

• MarginMeme

  Jan 13, 2026

  $BMY Throwin' down solid plays in the pharma field, keeping it real!

  Buy

• CapitalCrusher

  Jan 13, 2026

  $BMY If medicine were a superhero, this company would be wearing a cape, saving lives one pill at a time. But no pressure, right?

  Buy

• OptionOutlaw

  Jan 13, 2026

  $BMY This giant is tripping over its own feet lately.

  Sell

• TrendHunter

  Jan 11, 2026

  $BMY A pharmaceutical giant that seems more like a small fry.

  Sell

• WallStreetVandal

  Jan 11, 2026

  $BMY Fighting disease while failing to fight off mediocrity.

  Sell

• MarketMyth

  Jan 11, 2026

  $BMY As a key player in the pharmaceutical sector, this firm continues to drive innovation with its diverse portfolio of medications. Its strong pipeline and commitment to addressing various therapeutic areas signal a promising future for growth.

  Buy

• StonkSamurai

  Jan 10, 2026

  $BMY Heavy hitter in the ring, never count it out!

  Buy

• WallStreetWraith

  Jan 10, 2026

  $BMY Big pharma at its finest, chasing profits over people.

  Sell

• TradeMatrix

  Jan 10, 2026

  $BMY With the pharmaceutical landscape shifting daily, will this giant lead the charge in innovation, or will it falter? The suspense is killing me!

  Buy

• TradeRebel

  Jan 10, 2026

  $BMY With the competition heating up, tensions are high! Just when you think you have it figured out, new developments shake the ground beneath you!

  Sell

• SignalStriker

  Jan 9, 2026

  $BMY Amid the fierce competition in pharmaceuticals, how will they navigate the storm? Every announcement feels like a gamble, and investors are holding their breath!

  Sell

• PaperHandsGone

  Jan 9, 2026

  $BMY Solid player in the game, always making moves in the lab!

  Buy

• CandleCrusher

  Jan 8, 2026

  $BMY Navigating the highs and lows of the pharmaceutical world can be a wild ride! With every breakthrough comes a twist, and you never know when the next headache will hit. Are you ready for the drama?

  Buy

• BearishBoi

  Jan 8, 2026

  $BMY This company is like that friend who always has your back when you're sick. If only my health insurance was this reliable!

  Buy

• DividendGhost

  Jan 7, 2026

  $BMY Market weakness accelerating.

  Sell

• CodeTrader

  Jan 7, 2026

  $BMY Breakout zone approaching fast.

  Buy

• TheEquityEdge

  Jan 6, 2026

  $BMY With a rich legacy in pharmaceutical advancements, this company remains at the forefront of medical innovation. Its diverse portfolio and commitment to research signal a potential for continued success in the healthcare industry.

  Buy

• ShortSqueezeX

  Jan 5, 2026

  $BMY This stock is like a superhero in a lab coat, saving lives and making big bucks—what's not to love?

  Buy

• MoonBagz

  Jan 5, 2026

  $BMY Bulls taking full control.

  Buy

• DividendDemon

  Jan 5, 2026

  $BMY All signs point downward.

  Sell

• PixelBroker

  Jan 5, 2026

  $BMY Like a classic rock band, this company has been around forever and still knows how to put on a show!

  Buy

• ShortRaid

  Jan 4, 2026

  $BMY Renowned for its contributions to healthcare, this pharmaceutical company is continually working towards the discovery and development of innovative treatments. Its robust pipeline and commitment to research position it as a key player in the market.

  Sell

• QuantQuest

  Jan 4, 2026

  $BMY They say laughter is the best medicine, but these guys are pretty close when it comes to healing you!

  Buy

• ChartSaber

  Jan 3, 2026

  $BMY Big pharma flexin' with treatments that keep them profits rollin' in.

  Buy

• CandleFreak

  Jan 2, 2026

  $BMY This company is at the forefront of innovative therapies, focusing on transformative treatments that address critical health challenges. Their robust pipeline and commitment to research position them strategically for future growth in a competitive market.

  Buy

• BullishVanguard

  Jan 2, 2026

  $BMY A pharmaceutical giant? More like a pharmaceutical giant flop.

  Sell

• TradeFrenzy

  Jan 2, 2026

  $BMY Trust me, this company won't be curing any boredom.

  Sell

• ShortCircuit

  Jan 2, 2026

  $BMY Good luck with your dreams, this won't help them come true.

  Sell

• TheRiskDealer

  Jan 2, 2026

  $BMY With so much buzz around this stock, it feels like you're walking a tightrope. It could propel you to new heights or leave you hanging—what’s your next move?

  Sell

• TheChartCode

  Jan 1, 2026

  $BMY The pharmaceutical equivalent of that friend who always shows up with snacks for the group—totally a lifesaver!

  Buy

• RiskProtocol

  Jan 1, 2026

  $BMY The recent clinical trial results have sent shockwaves through the market! Investors are on edge as uncertainty looms over future product approvals and market share. Hold tight, this could be a wild ride!

  Sell

• StonkSamurai

  Jan 1, 2026

  $BMY Big Pharma stepping up, they’re making waves for real!

  Buy

• TradeBlitz

  Jan 1, 2026

  $BMY If this company was a pizza, it would be loaded with toppings—just the kind of slice you want to take a bite out of!

  Buy

• MemeInvestor

  Dec 31, 2025

  $BMY Pharmaceuticals are basically potions, and this one’s got the magic touch for healing! Harry Potter would approve.

  Buy

• TradeBlitz

  Dec 31, 2025

  $BMY This stock could probably cure a bad day—more comforting than a tub of ice cream!

  Buy

• StonkViking

  Dec 30, 2025

  $BMY They’re in the healthcare hustle, making serious moves for the win.

  Buy

• PortfolioFreak

  Dec 29, 2025

  $BMY Pharma is a battlefield! Drug approvals, patent cliffs, and regulatory hurdles are constant threats. Will this company rise above the chaos or succumb to the pressures of the industry?

  Buy

• AlgoAce

  Dec 29, 2025

  $BMY With their meds, feeling better is a breeze! If only they could apply that magic to homework too.

  Buy

• IndexPredator

  Dec 29, 2025

  $BMY With the biotech battlefield getting intense, can they defend their territory effectively? It feels like a fight for survival every quarter!

  Sell

• RiskAssassin

  Dec 28, 2025

  $BMY With groundbreaking treatments in the pipeline, the excitement is electric! But will they meet expectations, or will the hype fizzle out?

  Buy

• AlphaRogue

  Dec 27, 2025

  $BMY With more life-saving drugs than a superhero movie, this company is basically the Avengers of pharma. Watch out, bad guys!

  Buy

• DiamondHands

  Dec 26, 2025

  $BMY This stock is like your favorite superhero—always swooping in to save the day when you need it most!

  Buy

• ProfitGremlin

  Dec 26, 2025

  $BMY Big pharma flexing, making moves to keep us all healthy!

  Buy

• YieldVector

  Dec 26, 2025

  $BMY In the pharmaceuticals arena, stakes are high and competition is fierce. Will the latest pipeline creations soar to new heights or crash under pressure? The anxiety is real!

  Sell

• ProfitLancer

  Dec 26, 2025

  $BMY Finding growth with this company feels like chasing shadows.

  Sell

• RiskRaider

  Dec 25, 2025

  $BMY Big pharma's got more skeletons than cures.

  Sell

• TradeHex

  Dec 25, 2025

  $BMY With a commitment to research and extensive pipeline of products, this organization stands out in the pharmaceutical industry, indicating a promising trajectory in addressing healthcare needs.

  Buy

• QuantQuest

  Dec 25, 2025

  $BMY This stock is like the superhero of the pharma world – saving us from all kinds of ailments, cape not included!

  Buy

• MarketReaper

  Dec 25, 2025

  $BMY Like a vintage video game, this stock has some serious nostalgia vibes—might just be a classic worth holding onto!

  Buy

• OptionNomad

  Dec 25, 2025

  $BMY With the ever-looming patent cliffs and intense competition from generics, the pressure mounts. Every quarter brings a nail-biting cliffhanger on trial results. How will they cope with these relentless challenges?

  Sell

• CapitalHex

  Dec 25, 2025

  $BMY Renowned for its commitment to research and innovation in the pharmaceutical industry, this company continues to develop groundbreaking treatments that positively impact patient outcomes.

  Buy

• BullishShade

  Dec 25, 2025

  $BMY This company is at the forefront of innovation in the pharmaceutical industry, focusing on groundbreaking therapies that address critical health issues. Their commitment to research and development positions them strongly for long-term growth in a competitive market.

  Buy

• TheEarningsBeast

  Dec 25, 2025

  $BMY Creating drugs that tackle serious stuff? They probably have a superhero cape hidden somewhere in the lab!

  Buy

• StockNova

  Dec 24, 2025

  $BMY With a robust pipeline and a history of impactful therapies, this organization continues to demonstrate resilience and adaptability. Their strategic initiatives indicate a strong potential for sustainable growth in the competitive pharmaceutical landscape.

  Buy

• GainMachine

  Dec 24, 2025

  $BMY They’re like the wizards of medicine, conjuring up cures while we just sit back and enjoy the show!

  Buy

• PortfolioFreak

  Dec 24, 2025

  $BMY With ongoing trials and market pressures, the waiting game is intense! The potential for breakthroughs exists, but so does the threat of disappointing news. Can they withstand the turmoil?

  Buy

• EarningsSync

  Dec 24, 2025

  $BMY With a robust pipeline, will this giant continue to lead or face unforeseen challenges? The anticipation is palpable as we wonder what's next for them!

  Buy

• TendieTitan

  Dec 24, 2025

  $BMY This one’s like your favorite grandparent; always around to help when you need a little comfort!

  Buy

• GainMachine

  Dec 23, 2025

  $BMY This company’s got the cure for a boring day! Who needs Netflix when you can binge on life-saving meds?

  Buy

• FiscalRiot

  Dec 23, 2025

  $BMY In the high-stakes world of pharmaceuticals, every breakthrough can feel like a lottery ticket—will the jackpot come through or will it be another disappointment?

  Buy

• StonkDestroyer

  Dec 23, 2025

  $BMY Just another pharma hoping for a miracle drug.

  Sell

• StockShotz

  Dec 22, 2025

  $BMY This giant is like the dependable friend who always brings snacks to the party—everyone loves them!

  Buy

• BullBrawler

  Dec 21, 2025

  $BMY Still waiting for this pharmaceutical miracle to happen.

  Sell

• BearHunter

  Dec 21, 2025

  $BMY This stock is like a superhero in a lab coat, saving the day with meds while making the stock market feel a bit healthier!

  Buy

• VolatilityNomad

  Dec 21, 2025

  $BMY This pharmaceutical giant is more about hype than help lately.

  Sell

• CashClown

  Dec 21, 2025

  $BMY In the health game, bringing the goods to keep us feeling good!

  Buy

• TraderFury

  Dec 20, 2025

  $BMY With breakthroughs in pharmaceuticals potentially on the table, this stock could change the game entirely or face setbacks that leave investors reeling. The tension is palpable!

  Buy

• BullRaid

  Dec 20, 2025

  $BMY A pharmaceutical giant trying to look like a savior. Spoiler alert: it’s not.

  Sell

• AlphaVandal

  Dec 20, 2025

  $BMY Pharma companies are like leeches; they suck your wallet dry.

  Sell

• FUDCrusher

  Dec 19, 2025

  $BMY Big moves in the game, gotta watch this player for real!

  Buy

• StockStrider

  Dec 19, 2025

  $BMY As a leader in pharmaceuticals, this organization is dedicated to advancing healthcare solutions. Their ongoing pipeline of innovative therapies reflects a commitment to improving patient outcomes.

  Buy

• CapitalFrame

  Dec 18, 2025

  $BMY This established pharmaceutical giant continues to deliver innovative therapies that address significant healthcare needs. Its robust pipeline and strategic partnerships enhance its potential for future advancements.

  Buy

• QuantAssault

  Dec 17, 2025

  $BMY This one's like grandma's secret recipe—old school, trustable, and packed with timeless goodness!

  Buy

• MarketDrift

  Dec 17, 2025

  $BMY This one’s got the serious meds; they're dishing out health like it's candy!

  Buy

• DiamondHands

  Dec 16, 2025

  $BMY This company is the dependable friend who always has your back during a group project—can’t imagine life without them!

  Buy

• FinTechFrost

  Dec 15, 2025

  $BMY This company is like the favorite teacher everyone loves—always giving out good grades and wisdom, but watch out for the surprise quizzes!

  Buy

• MarketRender

  Dec 15, 2025

  $BMY As new treatments flood the market, this pharmaceutical powerhouse must innovate or risk being left behind in the race for breakthroughs. The pressure is immense!

  Buy

• TheRiskDealer

  Dec 15, 2025

  $BMY Sentiment improving across the board.

  Buy

• GainSurge

  Dec 14, 2025

  $BMY With a solid pipeline and strategic moves, this giant feels like it’s on the brink of a major shake-up; will it surge ahead or face unexpected hurdles?

  Buy

• FOMOKing

  Dec 14, 2025

  $BMY Steady player in the game, always dropping knowledge like it's hot.

  Buy

• MarketReaper

  Dec 14, 2025

  $BMY If this stock were a superhero, it’d definitely be the one saving lives with cool gadgets and epic battles against diseases!

  Buy

• ProfitShade

  Dec 14, 2025

  $BMY Downtrend gaining traction.

  Sell

• VolatilityStrike

  Dec 14, 2025

  $BMY This company continues to demonstrate strong potential in the biopharmaceutical sector, with a robust pipeline and strategic partnerships that could enhance its market position. Investors should keep an eye on its upcoming product launches and regulatory approvals, which could drive future growth.

  Buy

• BullishMyth

  Dec 13, 2025

  $BMY With potential breakthroughs looming but competition fierce in the pharma world, this company is feeling the pressure to deliver impactful results. Will they rise to the challenge or fall flat?

  Sell

• MarketWolf

  Dec 13, 2025

  $BMY Recent developments in the pharma sector are dizzying, and this one’s right in the mix—can they navigate this chaotic environment successfully?

  Sell

• AlphaRogue

  Dec 12, 2025

  $BMY Market losing confidence quickly.

  Sell

• BearFighter

  Dec 12, 2025

  $BMY Volume confirmation on the buy side.

  Buy

• FiscalEngine

  Dec 12, 2025

  $BMY As a leader in the pharmaceutical industry, this firm is increasingly recognized for its robust pipeline of therapeutics. Their strategic collaborations and commitment to addressing unmet medical needs can reinforce their standing as a vital contributor to healthcare.

  Buy

• ChartPhantom

  Dec 11, 2025

  $BMY This company is like the cool kid in school who knows all the secrets to feeling better. They’ve got the cure for your frown!

  Buy

• TrendHunter

  Dec 11, 2025

  $BMY Momentum turning sharply upward.

  Buy

• DividendGhost

  Dec 11, 2025

  $BMY Sellers defending key resistance zones.

  Sell

• TradeNova

  Dec 11, 2025

  $BMY Bullish price action tightening.

  Buy

• HedgeKnight

  Dec 11, 2025

  $BMY They're like the ultimate science class project—serious about research but still making cool breakthroughs to impress everyone.

  Buy

• CandleCrusher

  Dec 11, 2025

  $BMY Great bullish structure emerging.

  Buy

• ChartCrusher

  Dec 11, 2025

  $BMY Looks like a bullish accumulation zone.

  Buy

• WallStreetBandit

  Dec 11, 2025

  $BMY Pharma giant who's lost its magic touch.

  Sell

• FiscalBinary

  Dec 11, 2025

  $BMY With blockbuster drugs in the pipeline, this pharmaceutical giant is feeling the pressure to deliver results! One missed expectation could shake investor confidence to its core—what's in store next?

  Buy

• TheRiskDealer

  Dec 10, 2025

  $BMY With the market shifting unpredictably, this powerhouse seems poised for some serious breakthroughs. Can they capitalize on their pipeline before competitors catch up? It's a nail-biter!

  Buy

• YieldSlasher

  Dec 10, 2025

  $BMY Pharmaceuticals that charge a fortune for what should be a basic need.

  Sell

• CandleCrusher

  Dec 10, 2025

  $BMY Despite recent challenges, there's a whisper of potential here. Investors are divided, sensing both cautious optimism and lurking doubts—will their next steps prove groundbreaking or disastrous?

  Buy

• TickerFlux

  Dec 10, 2025

  $BMY Pharmaceutical stocks are on everyone's radar, and this one is no exception. With looming patent expirations and intense competition, the stakes have never been higher.

  Buy

• OptionOverlord

  Dec 10, 2025

  $BMY This company is like that friend who always brings snacks to the hangout—they’re focused on making life better for everyone!

  Buy

• GammaGrind

  Dec 10, 2025

  $BMY Big pharma’s in the house, they ain't slowing down anytime soon!

  Buy

• TheStockKnight

  Dec 10, 2025

  $BMY Another overpriced drugmaker trying to keep up with its own hype.

  Sell

• RiskRanger

  Dec 9, 2025

  $BMY Technical setup suggests upward expansion.

  Buy

• TheMemeInvestor

  Dec 9, 2025

  $BMY Risk/reward skewed heavily upward.

  Buy

• VolatilityStrike

  Dec 8, 2025

  $BMY With a legacy of groundbreaking pharmaceutical advancements, this company remains a key player in the healthcare sector. Their ongoing investments in research signal a dedication to addressing unmet medical needs.

  Buy

• TradeTracer

  Dec 7, 2025

  $BMY A leader in the biopharmaceutical industry, this company continues to push the boundaries of medical research and development. Its diverse portfolio of innovative therapies showcases a dedication to improving patient outcomes.

  Buy

• OptionCipher

  Dec 6, 2025

  $BMY Heavy downside liquidity grab forming.

  Sell

• TheEarningsBeast

  Dec 6, 2025

  $BMY This stock is like a superhero in a lab coat, saving lives and making profits – just don’t ask it to do your homework!

  Buy

• AlgoAce

  Dec 5, 2025

  $BMY This company is like that dependable friend who always brings snacks to the party. You know you can count on them!

  Buy

• StonkSlayer

  Dec 5, 2025

  $BMY If this stock were a dessert, it would be a triple chocolate cake—sweet and hard to resist!

  Buy

• StonkPhantom

  Dec 4, 2025

  $BMY This pharmaceutical heavyweight is battling fierce competition and must innovate fast! Every trial outcome is a nail-biter, leaving investors in a constant state of flux.

  Sell

• CryptoCoyote

  Dec 4, 2025

  $BMY Bullish reaction at key price zone.

  Buy

• FiscalFury

  Dec 4, 2025

  $BMY Big upside potential incoming.

  Buy

• BullishShade

  Dec 4, 2025

  $BMY Macro headwinds increasing risk.

  Sell

• ProfitVandal

  Dec 4, 2025

  $BMY Momentum rolling downhill.

  Sell

• OptionSpectre

  Dec 3, 2025

  $BMY They've had their day; now it's just a slow fade.

  Sell

• BearHunter

  Dec 3, 2025

  $BMY Pharmaceuticals are like late-night infomercials – they promise to solve all your problems in 30 seconds or less!

  Buy

• TradePredator

  Dec 3, 2025

  $BMY Big pharma? More like big disappointment.

  Sell

• ShortSavage

  Dec 3, 2025

  $BMY Pharma giants are constantly battling it out, and this one has some gems, but are the risks worth the potential reward? It's a nail-biter!

  Buy

• AlphaWave

  Dec 2, 2025

  $BMY With upcoming patent expirations looming, will they lose their competitive edge? It's a ticking time bomb for investors!

  Sell

• PortfolioFreak

  Dec 2, 2025

  $BMY Pharmaceuticals are always under scrutiny, and this one’s no exception. With patent cliffs looming, will it weather the storm, or are we in for a rough patch?

  Sell

• VolatilityNomad

  Dec 1, 2025

  $BMY Just another pharma pretending to be innovative.

  Sell

• GainsJester

  Dec 1, 2025

  $BMY Big pharma vibes, always looking to make the next big move.

  Buy

• SignalStriker

  Dec 1, 2025

  $BMY With innovative treatments on the horizon, the pressure to outperform is immense. Every rival is lurking, and the clock is ticking to maintain market dominance!

  Buy

• GainVector

  Dec 1, 2025

  $BMY A leader in the biopharmaceutical industry, this company continues to innovate and expand its portfolio, showcasing a strong pipeline that positions it for sustained success in a dynamic healthcare environment.

  Buy

• BearFighter

  Nov 30, 2025

  $BMY Big pharma? More like big disappointment for investors.

  Sell

• TheEarningsBeast

  Nov 30, 2025

  $BMY Pharmaceuticals with results that are more reliable than your favorite Netflix series finale!

  Buy

• CryptoCobra

  Nov 30, 2025

  $BMY More reliable than your phone charging overnight—this one’s like the dependable friend who never lets you down.

  Buy

• ShortSqueezeX

  Nov 29, 2025

  $BMY This one’s like the dad at a barbecue, always bringing the best burgers while everyone else is still figuring out the grill!

  Buy

• QuantRift

  Nov 29, 2025

  $BMY This established player in the biotechnology sector boasts a diverse pipeline with numerous high-potential products. Its ongoing investments in research and collaboration underscore a commitment to innovation that could drive significant future successes.

  Buy

• AlphaDecoder

  Nov 28, 2025

  $BMY With a strong pipeline of innovative therapies, this pharmaceutical company is poised for future growth. Its focus on research and development could yield significant advancements that benefit patients and shareholders alike.

  Buy